Overview

Safety, Tolerability and Pharmacokinetics of BIIB118 (PF-05251749)

Status:
Completed
Trial end date:
2015-10-31
Target enrollment:
Participant gender:
Summary
This is a First in human (FIH) single ascending dose study to evaluate the safety, tolerability and pharmacokinetics (PKs) of BIIB118 following single oral doses in healthy human subjects
Phase:
Phase 1
Details
Lead Sponsor:
Biogen
Pfizer